Treatment of antineutrophil cytoplasmic antibodyassociated vasculitis with rituximab

Rodrigo Cartin-Cebaa, Fernando C. Fervenzab, Ulrich Specks

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


RTX is the first proven alternative to CYC for remission induction in severe GPA and MPA. RTX is the preferred agent for patients presenting with severe disease flares, and its use had become the de facto standard of care for patients with chronically relapsing refractory GPA. Its use in EGPA requires further investigation.

Original languageEnglish (US)
Pages (from-to)15-23
Number of pages9
JournalCurrent opinion in rheumatology
Issue number1
StatePublished - Jan 1 2012


  • Antineutrophil cytoplasmic antibody
  • Antineutrophil cytoplasmic antibody associated vasculitis
  • Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
  • Granulomatosis with polyangiitis (Wegener's granulomatosis)
  • Microscopic polyangiitis
  • Rituximab
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Treatment of antineutrophil cytoplasmic antibodyassociated vasculitis with rituximab'. Together they form a unique fingerprint.

Cite this